Finally, a subgroup of patients (n = 65 patients) was comprehensively analyzed for presence of circulating tumor cells (CTCs) and AR-V3 expression in CTCs (irrespective of isoform) before starting ARTA treatment (abiraterone = 46, enzalutamide = 19). The gene discussed is AR; the disease is neoplasm.